Recent M&A activity indicates a potential resurgence in the appetites of larger companies for psychiatric drug development, but experts say the space may not offer a sufficient risk-reward proposition for R&D.
Tag Archive for: neuropsychiatric
Two biotechs, Nvelop Therapeutics and Seaport Therapeutics, emerged from stealth Tuesday with $100 million in financing as they look to target the neuropsychiatric and gene editing spaces, respectively.
Psychedelic and psychedelic-assisted therapies in the neuropsychiatric space have stalled for decades.